Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease save search
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Published: 2024-04-16 (Crawled : 05:00) - globenewswire.com
ARGX | $374.21 -0.55% 150K
|
Health Technology
|
| O: -4.09%
H: 0.0%
C: 0.0%
disease vyvgart for
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.87 1.78% 91K
|
n/a
| Email alert
Add to watchlist
disease treatment for meeting therapeutics
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
LGVN P 3 d | $3.305 12.8% 4.3M
|
|
| O: 41.42%
H: 42.68%
C: 22.59%
conference disease association alzheimer’s presentation international research for trial
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI M | $4.91 -0.81% 520K
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
IPSC | $3.25 -11.44% 110K
|
Professional, Scientific, and T...
|
| O: 3.39%
H: 11.53%
C: 2.02%
disease million pipeline acquisition expansion therapeutics
Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
Published: 2024-04-11 (Crawled : 11:00) - prnewswire.com
EVGN | $0.6863 48K
|
Health Technology
|
| O: -0.87%
H: 0.0%
C: 0.0%
conference disease meeting week
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
ATHA | $2.07 0.49% 110K
|
Health Technology
|
| O: 4.9%
H: 6.03%
C: 3.11%
fosgonimeton pharma disease alzheimer’s publication treatment preclinical
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
SILO | $1.9 15K
|
Finance and Insurance
|
| O: -0.46%
H: 2.75%
C: -3.67%
pharma disease alzheimer’s acquire spc-14
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.615 -5.56% 700K
|
Health Technology
|
| O: 0.57%
H: 11.65%
C: 4.55%
disease control treatment trial therapeutics
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
CRL | $232.39 -1.5% 130K
|
Commercial Services
|
| O: 0.93%
H: 0.36%
C: -0.05%
rare disease collaboration therapeutics therapy
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
Published: 2024-04-09 (Crawled : 12:30) - neurosense.investorroom.com
NRSN 4 d | $1.53 73K
|
|
| O: 8.14%
H: 3.71%
C: -7.53%
disease order diagnostics neurodegenerative
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
NAMS | $19.66 -0.41% 1.1M
|
n/a
|
| O: -6.3%
H: 2.72%
C: -2.67%
pharma disease global trial cardiovascular
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $25.73 -0.7% 17M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
ICAD | $1.57 -3.68% 44K
|
Technology Services
|
| O: 5.7%
H: 11.98%
C: 7.78%
disease risk meeting heart cardiology
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
IGXT | $0.17 37K
|
Manufacturing
|
| O: -5.24%
H: 8.65%
C: 8.65%
versafilm first disease montelukast parkinson’s trial
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
BRTX | $1.42 7.58% 10M
|
Professional, Scientific, and T...
|
| O: -1.5%
H: 0.0%
C: -2.29%
brtx-100 disease trial
New survey uncovers lack of awareness around heart valve disease and risk factors among women
Published: 2024-04-07 (Crawled : 12:20) - prnewswire.com
MDT | $79.43 -1.0% 4M
|
Health Technology
| Email alert
Add to watchlist
disease risk women heart
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Published: 2024-04-06 (Crawled : 20:20) - globenewswire.com
AMRN | $0.9 -2.03% 500K
|
Health Technology
| Email alert
Add to watchlist
disease cardiovascular show
Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research
Published: 2024-04-05 (Crawled : 11:00) - prnewswire.com
LH | $204.32 0.49% 330K
|
Health Services
|
| O: -0.6%
H: 0.0%
C: 0.0%
OPK | $1.21 -1.63% 2M
|
Health Technology
|
| O: -0.73%
H: 0.74%
C: -0.74%
labcorp disease research molecular
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
JAGX | $0.1771 49.07% 540M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
PALI | $5.51 32.45% 28M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.